Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts

por TSUKIHARA, HIROSHI, NAKAGAWA, FUMIO, SAKAMOTO, KAZUKI, ISHIDA, KEIJI, TANAKA, NOZOMU, OKABE, HIROYUKI, UCHIDA, JUNJI, MATSUO, KENICHI, TAKECHI, TEIJI
Publicado 2015

Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy

por Shibutani, Toshihiro, Goto, Risa, Miyazaki, Isao, Hashimoto, Akihiro, Suzuki, Takamasa, Ishida, Keiji, Haruma, Tomonori, Osada, Toshihiro, Harada, Takafumi, Fujita, Hidenori, Ohkubo, Shuichi
Publicado 2023

Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2′-deoxy-5-fluorouridine into DNA

por SAKAMOTO, KAZUKI, YOKOGAWA, TATSUSHI, UENO, HIROYUKI, OGUCHI, KEI, KAZUNO, HIROMI, ISHIDA, KEIJI, TANAKA, NOZOMU, OSADA, AKIKO, YAMADA, YUKARI, OKABE, HIROYUKI, MATSUO, KENICHI
Publicado 2015

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

por TANAKA, NOZOMU, SAKAMOTO, KAZUKI, OKABE, HIROYUKI, FUJIOKA, AKIO, YAMAMURA, KEISUKE, NAKAGAWA, FUMIO, NAGASE, HIDEKI, YOKOGAWA, TATSUSHI, OGUCHI, KEI, ISHIDA, KEIJI, OSADA, AKIKO, KAZUNO, HIROMI, YAMADA, YUKARI, MATSUO, KENICHI
Publicado 2014

TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia

por Ochiiwa, Hiroaki, Ailiken, Guzhanuer, Yokoyama, Masataka, Yamagata, Kazuyuki, Nagano, Hidekazu, Yoshimura, Chihoko, Muraoka, Hiromi, Ishida, Keiji, Haruma, Tomonori, Nakayama, Akitoshi, Hashimoto, Naoko, Murata, Kazutaka, Nishimura, Motoi, Kawashima, Yusuke, Ohara, Osamu, Ohkubo, Shuichi, Tanaka, Tomoaki
Publicado 2021

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

por Miyazaki, Isao, Odintsov, Igor, Ishida, Keiji, Lui, Allan J. W., Kato, Masanori, Suzuki, Tatsuya, Zhang, Tom, Wakayama, Kentaro, Kurth, Renate I., Cheng, Ryan, Fujita, Hidenori, Delasos, Lukas, Vojnic, Morana, Khodos, Inna, Yamada, Yukari, Ishizawa, Kota, Mattar, Marissa S., Funabashi, Kaoru, Chang, Qing, Ohkubo, Shuichi, Yano, Wakako, Terada, Ryuichiro, Giuliano, Claudio, Lu, Yue Christine, Bonifacio, Annalisa, Kunte, Siddharth, Davare, Monika A., Cheng, Emily H., de Stanchina, Elisa, Lovati, Emanuela, Iwasawa, Yoshikazu, Ladanyi, Marc, Somwar, Romel
Publicado 2023

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

por Miyazaki, Isao, Odintsov, Igor, Ishida, Keiji, Lui, Allan J. W., Kato, Masanori, Suzuki, Tatsuya, Zhang, Tom, Wakayama, Kentaro, Kurth, Renate I., Cheng, Ryan, Fujita, Hidenori, Delasos, Lukas, Vojnic, Morana, Khodos, Inna, Yamada, Yukari, Ishizawa, Kota, Mattar, Marissa S., Funabashi, Kaoru, Chang, Qing, Ohkubo, Shuichi, Yano, Wakako, Terada, Ryuichiro, Giuliano, Claudio, Lu, Yue Christine, Bonifacio, Annalisa, Kunte, Siddharth, Davare, Monika A., Cheng, Emily H., de Stanchina, Elisa, Lovati, Emanuela, Iwasawa, Yoshikazu, Ladanyi, Marc, Somwar, Romel
Publicado 2023